
|Articles|October 20, 2008
Novel glaucoma solution enters trials
INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement from Inspire Pharmaceuticals Inc.
Advertisement
INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement made by Inspire Pharmaceuticals Inc.
The Rho kinase inhibitor interferes with the actin cytoskeleton of the trabecular meshwork to lower intraocular pressure (IOP).
This placebo-controlled dose-escalating trial will appraise the compound's safety, efficacy and tolerability in early stage glaucoma or ocular hypertension.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy
3
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
4
Port Delivery System Therapies in Retinal Vascular Diseases
5






















